Evaluation of structural progression in arrhythmogenic right ventricular dysplasia/cardiomyopathy

Thomas P. Mast, Cynthia A. James, Hugh Calkins, Arco J. Teske, Crystal Tichnell, Brittney Murray, Peter Loh, Stuart D. Russell, Birgitta K. Velthuis, Daniel P. Judge, Dennis Dooijes, Ryan J. Tedford, Jeroen F. Van Der Heijden, Harikrishna Tandri, Richard N. Hauer, Theodore P. Abraham, Pieter A. Doevendans, Anneline S.J.M. Te Riele, Maarten J. Cramer

Research output: Research - peer-reviewArticle

Abstract

IMPORTANCE: Considerable research has described the arrhythmic course of arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). However, objective data characterizing structural progression, such as ventricular enlargement and cardiac dysfunction, in ARVD/C are relatively scarce. OBJECTIVES: To define the extent of structural progression, identify determinants of structural progression, and determine the association between structural progression and electrocardiographic (ECG) changes in patients with ARVD/C. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, first- and last-available echocardiograms of 85 patients with ARVD/C fulfilling 2010 Task Force diagnostic criteria (TFC) from a transatlantic ARVD/C registry were retrospectively compared to assess structural disease progression. Right ventricular (RV) size and systolic function between baseline and last follow-up were compared. The RV size was determined by RV outflow tract dimension, and RV and left ventricular (LV) systolic function were determined by RV fractional area change (RV-FAC) and LV ejection fraction (LVEF), respectively. Multivariable logistic regression was used to study associations between baseline characteristics and the occurrence of structural progression. MAIN OUTCOMES AND MEASURES: The main outcome was the change in variables indicating structural progression. Secondary outcomes were the correlation with electrical progression and identification of the association between baseline characteristics and occurence structural progression. RESULTS: Among the 85 patients with ARVD/C, mean (SD) age at baseline was 42.8 (14.4) years and 47 (55%) were men. After a mean (SD) follow-up of 6.4 (2.5) years, RV outflow tract dimension increased from 35 mm (interquartile range [IQR], 31 to 39) to 37 mm (IQR, 33 to 41) (P < .001), RV-FAC decreased from 39% (IQR, 33% to 44%) to 34% (IQR, 24% to 42%) (P < .001) (rate −3.3% per 5 years; IQR, −8.9% to 1.2%), indicating large interpatient variability. The LVEF decreased from 55% (IQR, 52% to 60%) to 54% (IQR, 49% to 57%) (P = .001) (rate, −0.2% per 5 years; IQR, −6.5% to 1.7%). Forty examinations were reanalyzed to establish the measurement error. Patients exceeding the measurement error by ±2 SDs were identified with significant progressive disease for RV, with a decrease in RV-FAC greater than 10% (n = 21) and, for LV, a decrease in LVEF greater than 7% (n = 23). Progression of RV disease was associated with depolarization criteria at baseline (odds ratio [OR], 9.0; 95% CI, 1.1-74.2; P = .04), whereas progression of LV disease was associated with phospholamban (PLN) mutation (OR, 8.8; 95% CI, 2.1-37.2; P = .003). There was no association between progressive RV/LV structural disease and newly developed ECG TFC. CONCLUSIONS AND RELEVANCE: Structural dysfunction in ARVD/C is progressive with substantial interpatient variability. Significant structural RV progression was associated with prior depolarization abnormalities, whereas LV progression is modified by genetic background. Structural progression was not associated with development of new ECG TFC. The results of this study pave the way for designing and launching trials aimed at reducing structural progression in patients with ARVD/C.

LanguageEnglish (US)
Pages293-302
Number of pages10
JournalJAMA Cardiology
Volume2
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Arrhythmogenic Right Ventricular Dysplasia
Advisory Committees
Odds Ratio
Left Ventricular Function
Stroke Volume
Registries
Disease Progression
Cohort Studies
Logistic Models
Mutation
Research
phospholamban
Genetic Background

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Evaluation of structural progression in arrhythmogenic right ventricular dysplasia/cardiomyopathy. / Mast, Thomas P.; James, Cynthia A.; Calkins, Hugh; Teske, Arco J.; Tichnell, Crystal; Murray, Brittney; Loh, Peter; Russell, Stuart D.; Velthuis, Birgitta K.; Judge, Daniel P.; Dooijes, Dennis; Tedford, Ryan J.; Van Der Heijden, Jeroen F.; Tandri, Harikrishna; Hauer, Richard N.; Abraham, Theodore P.; Doevendans, Pieter A.; Te Riele, Anneline S.J.M.; Cramer, Maarten J.

In: JAMA Cardiology, Vol. 2, No. 3, 01.03.2017, p. 293-302.

Research output: Research - peer-reviewArticle

Mast, TP, James, CA, Calkins, H, Teske, AJ, Tichnell, C, Murray, B, Loh, P, Russell, SD, Velthuis, BK, Judge, DP, Dooijes, D, Tedford, RJ, Van Der Heijden, JF, Tandri, H, Hauer, RN, Abraham, TP, Doevendans, PA, Te Riele, ASJM & Cramer, MJ 2017, 'Evaluation of structural progression in arrhythmogenic right ventricular dysplasia/cardiomyopathy' JAMA Cardiology, vol 2, no. 3, pp. 293-302. DOI: 10.1001/jamacardio.2016.5034
Mast, Thomas P. ; James, Cynthia A. ; Calkins, Hugh ; Teske, Arco J. ; Tichnell, Crystal ; Murray, Brittney ; Loh, Peter ; Russell, Stuart D. ; Velthuis, Birgitta K. ; Judge, Daniel P. ; Dooijes, Dennis ; Tedford, Ryan J. ; Van Der Heijden, Jeroen F. ; Tandri, Harikrishna ; Hauer, Richard N. ; Abraham, Theodore P. ; Doevendans, Pieter A. ; Te Riele, Anneline S.J.M. ; Cramer, Maarten J./ Evaluation of structural progression in arrhythmogenic right ventricular dysplasia/cardiomyopathy. In: JAMA Cardiology. 2017 ; Vol. 2, No. 3. pp. 293-302
@article{ab63de5b62524e938f4b1038a10755da,
title = "Evaluation of structural progression in arrhythmogenic right ventricular dysplasia/cardiomyopathy",
abstract = "IMPORTANCE: Considerable research has described the arrhythmic course of arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). However, objective data characterizing structural progression, such as ventricular enlargement and cardiac dysfunction, in ARVD/C are relatively scarce. OBJECTIVES: To define the extent of structural progression, identify determinants of structural progression, and determine the association between structural progression and electrocardiographic (ECG) changes in patients with ARVD/C. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, first- and last-available echocardiograms of 85 patients with ARVD/C fulfilling 2010 Task Force diagnostic criteria (TFC) from a transatlantic ARVD/C registry were retrospectively compared to assess structural disease progression. Right ventricular (RV) size and systolic function between baseline and last follow-up were compared. The RV size was determined by RV outflow tract dimension, and RV and left ventricular (LV) systolic function were determined by RV fractional area change (RV-FAC) and LV ejection fraction (LVEF), respectively. Multivariable logistic regression was used to study associations between baseline characteristics and the occurrence of structural progression. MAIN OUTCOMES AND MEASURES: The main outcome was the change in variables indicating structural progression. Secondary outcomes were the correlation with electrical progression and identification of the association between baseline characteristics and occurence structural progression. RESULTS: Among the 85 patients with ARVD/C, mean (SD) age at baseline was 42.8 (14.4) years and 47 (55%) were men. After a mean (SD) follow-up of 6.4 (2.5) years, RV outflow tract dimension increased from 35 mm (interquartile range [IQR], 31 to 39) to 37 mm (IQR, 33 to 41) (P < .001), RV-FAC decreased from 39% (IQR, 33% to 44%) to 34% (IQR, 24% to 42%) (P < .001) (rate −3.3% per 5 years; IQR, −8.9% to 1.2%), indicating large interpatient variability. The LVEF decreased from 55% (IQR, 52% to 60%) to 54% (IQR, 49% to 57%) (P = .001) (rate, −0.2% per 5 years; IQR, −6.5% to 1.7%). Forty examinations were reanalyzed to establish the measurement error. Patients exceeding the measurement error by ±2 SDs were identified with significant progressive disease for RV, with a decrease in RV-FAC greater than 10% (n = 21) and, for LV, a decrease in LVEF greater than 7% (n = 23). Progression of RV disease was associated with depolarization criteria at baseline (odds ratio [OR], 9.0; 95% CI, 1.1-74.2; P = .04), whereas progression of LV disease was associated with phospholamban (PLN) mutation (OR, 8.8; 95% CI, 2.1-37.2; P = .003). There was no association between progressive RV/LV structural disease and newly developed ECG TFC. CONCLUSIONS AND RELEVANCE: Structural dysfunction in ARVD/C is progressive with substantial interpatient variability. Significant structural RV progression was associated with prior depolarization abnormalities, whereas LV progression is modified by genetic background. Structural progression was not associated with development of new ECG TFC. The results of this study pave the way for designing and launching trials aimed at reducing structural progression in patients with ARVD/C.",
author = "Mast, {Thomas P.} and James, {Cynthia A.} and Hugh Calkins and Teske, {Arco J.} and Crystal Tichnell and Brittney Murray and Peter Loh and Russell, {Stuart D.} and Velthuis, {Birgitta K.} and Judge, {Daniel P.} and Dennis Dooijes and Tedford, {Ryan J.} and {Van Der Heijden}, {Jeroen F.} and Harikrishna Tandri and Hauer, {Richard N.} and Abraham, {Theodore P.} and Doevendans, {Pieter A.} and {Te Riele}, {Anneline S.J.M.} and Cramer, {Maarten J.}",
year = "2017",
month = "3",
doi = "10.1001/jamacardio.2016.5034",
volume = "2",
pages = "293--302",
journal = "JAMA Cardiology",
issn = "2380-6583",
number = "3",

}

TY - JOUR

T1 - Evaluation of structural progression in arrhythmogenic right ventricular dysplasia/cardiomyopathy

AU - Mast,Thomas P.

AU - James,Cynthia A.

AU - Calkins,Hugh

AU - Teske,Arco J.

AU - Tichnell,Crystal

AU - Murray,Brittney

AU - Loh,Peter

AU - Russell,Stuart D.

AU - Velthuis,Birgitta K.

AU - Judge,Daniel P.

AU - Dooijes,Dennis

AU - Tedford,Ryan J.

AU - Van Der Heijden,Jeroen F.

AU - Tandri,Harikrishna

AU - Hauer,Richard N.

AU - Abraham,Theodore P.

AU - Doevendans,Pieter A.

AU - Te Riele,Anneline S.J.M.

AU - Cramer,Maarten J.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - IMPORTANCE: Considerable research has described the arrhythmic course of arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). However, objective data characterizing structural progression, such as ventricular enlargement and cardiac dysfunction, in ARVD/C are relatively scarce. OBJECTIVES: To define the extent of structural progression, identify determinants of structural progression, and determine the association between structural progression and electrocardiographic (ECG) changes in patients with ARVD/C. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, first- and last-available echocardiograms of 85 patients with ARVD/C fulfilling 2010 Task Force diagnostic criteria (TFC) from a transatlantic ARVD/C registry were retrospectively compared to assess structural disease progression. Right ventricular (RV) size and systolic function between baseline and last follow-up were compared. The RV size was determined by RV outflow tract dimension, and RV and left ventricular (LV) systolic function were determined by RV fractional area change (RV-FAC) and LV ejection fraction (LVEF), respectively. Multivariable logistic regression was used to study associations between baseline characteristics and the occurrence of structural progression. MAIN OUTCOMES AND MEASURES: The main outcome was the change in variables indicating structural progression. Secondary outcomes were the correlation with electrical progression and identification of the association between baseline characteristics and occurence structural progression. RESULTS: Among the 85 patients with ARVD/C, mean (SD) age at baseline was 42.8 (14.4) years and 47 (55%) were men. After a mean (SD) follow-up of 6.4 (2.5) years, RV outflow tract dimension increased from 35 mm (interquartile range [IQR], 31 to 39) to 37 mm (IQR, 33 to 41) (P < .001), RV-FAC decreased from 39% (IQR, 33% to 44%) to 34% (IQR, 24% to 42%) (P < .001) (rate −3.3% per 5 years; IQR, −8.9% to 1.2%), indicating large interpatient variability. The LVEF decreased from 55% (IQR, 52% to 60%) to 54% (IQR, 49% to 57%) (P = .001) (rate, −0.2% per 5 years; IQR, −6.5% to 1.7%). Forty examinations were reanalyzed to establish the measurement error. Patients exceeding the measurement error by ±2 SDs were identified with significant progressive disease for RV, with a decrease in RV-FAC greater than 10% (n = 21) and, for LV, a decrease in LVEF greater than 7% (n = 23). Progression of RV disease was associated with depolarization criteria at baseline (odds ratio [OR], 9.0; 95% CI, 1.1-74.2; P = .04), whereas progression of LV disease was associated with phospholamban (PLN) mutation (OR, 8.8; 95% CI, 2.1-37.2; P = .003). There was no association between progressive RV/LV structural disease and newly developed ECG TFC. CONCLUSIONS AND RELEVANCE: Structural dysfunction in ARVD/C is progressive with substantial interpatient variability. Significant structural RV progression was associated with prior depolarization abnormalities, whereas LV progression is modified by genetic background. Structural progression was not associated with development of new ECG TFC. The results of this study pave the way for designing and launching trials aimed at reducing structural progression in patients with ARVD/C.

AB - IMPORTANCE: Considerable research has described the arrhythmic course of arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). However, objective data characterizing structural progression, such as ventricular enlargement and cardiac dysfunction, in ARVD/C are relatively scarce. OBJECTIVES: To define the extent of structural progression, identify determinants of structural progression, and determine the association between structural progression and electrocardiographic (ECG) changes in patients with ARVD/C. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, first- and last-available echocardiograms of 85 patients with ARVD/C fulfilling 2010 Task Force diagnostic criteria (TFC) from a transatlantic ARVD/C registry were retrospectively compared to assess structural disease progression. Right ventricular (RV) size and systolic function between baseline and last follow-up were compared. The RV size was determined by RV outflow tract dimension, and RV and left ventricular (LV) systolic function were determined by RV fractional area change (RV-FAC) and LV ejection fraction (LVEF), respectively. Multivariable logistic regression was used to study associations between baseline characteristics and the occurrence of structural progression. MAIN OUTCOMES AND MEASURES: The main outcome was the change in variables indicating structural progression. Secondary outcomes were the correlation with electrical progression and identification of the association between baseline characteristics and occurence structural progression. RESULTS: Among the 85 patients with ARVD/C, mean (SD) age at baseline was 42.8 (14.4) years and 47 (55%) were men. After a mean (SD) follow-up of 6.4 (2.5) years, RV outflow tract dimension increased from 35 mm (interquartile range [IQR], 31 to 39) to 37 mm (IQR, 33 to 41) (P < .001), RV-FAC decreased from 39% (IQR, 33% to 44%) to 34% (IQR, 24% to 42%) (P < .001) (rate −3.3% per 5 years; IQR, −8.9% to 1.2%), indicating large interpatient variability. The LVEF decreased from 55% (IQR, 52% to 60%) to 54% (IQR, 49% to 57%) (P = .001) (rate, −0.2% per 5 years; IQR, −6.5% to 1.7%). Forty examinations were reanalyzed to establish the measurement error. Patients exceeding the measurement error by ±2 SDs were identified with significant progressive disease for RV, with a decrease in RV-FAC greater than 10% (n = 21) and, for LV, a decrease in LVEF greater than 7% (n = 23). Progression of RV disease was associated with depolarization criteria at baseline (odds ratio [OR], 9.0; 95% CI, 1.1-74.2; P = .04), whereas progression of LV disease was associated with phospholamban (PLN) mutation (OR, 8.8; 95% CI, 2.1-37.2; P = .003). There was no association between progressive RV/LV structural disease and newly developed ECG TFC. CONCLUSIONS AND RELEVANCE: Structural dysfunction in ARVD/C is progressive with substantial interpatient variability. Significant structural RV progression was associated with prior depolarization abnormalities, whereas LV progression is modified by genetic background. Structural progression was not associated with development of new ECG TFC. The results of this study pave the way for designing and launching trials aimed at reducing structural progression in patients with ARVD/C.

UR - http://www.scopus.com/inward/record.url?scp=85031413545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031413545&partnerID=8YFLogxK

U2 - 10.1001/jamacardio.2016.5034

DO - 10.1001/jamacardio.2016.5034

M3 - Article

VL - 2

SP - 293

EP - 302

JO - JAMA Cardiology

T2 - JAMA Cardiology

JF - JAMA Cardiology

SN - 2380-6583

IS - 3

ER -